1232 related articles for article (PubMed ID: 24074802)
1. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
2. Immune approaches to the treatment of breast cancer, around the corner?
Criscitiello C; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Adamoli L; Goldhirsch A; Curigliano G
Breast Cancer Res; 2014 Feb; 16(1):204. PubMed ID: 25774617
[TBL] [Abstract][Full Text] [Related]
3. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
4. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of breast cancer.
Wright SE
Expert Opin Biol Ther; 2012 Apr; 12(4):479-90. PubMed ID: 22413825
[TBL] [Abstract][Full Text] [Related]
11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
12. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy for melanoma: current status and future directions.
Terando AM; Faries MB; Morton DL
Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.
Arlen PM; Wood LV
Expert Rev Vaccines; 2012 Mar; 11(3):287-302. PubMed ID: 22380822
[TBL] [Abstract][Full Text] [Related]
16. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
17. Immunology and breast cancer: therapeutic cancer vaccines.
Curigliano G; Rescigno M; Goldhirsch A
Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
[TBL] [Abstract][Full Text] [Related]
18. The three Es of cancer immunoediting.
Dunn GP; Old LJ; Schreiber RD
Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
[TBL] [Abstract][Full Text] [Related]
19. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
Bergado Báez G; Hernández Fernández DR; Mazorra Herrera Z; Sánchez Ramírez B
Semin Oncol; 2018 Jan; 45(1-2):75-83. PubMed ID: 30318087
[TBL] [Abstract][Full Text] [Related]
20. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
